Bionomics American Depository Shares (BNOX) Stock Overview

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.

BNOX Stock Information

Symbol

BNOX

Address

200 Greenhill RoadEastwood, SA 5063Australia

Founded

Trading hours

Website

https://www.bionomics.com.au

Country

🇦🇺 Australia

Phone Number

61 8 8150 7400

Bionomics American Depository Shares (BNOX) Price Chart

Bionomics American Depository Shares Overview: Key Details and Summary

Stock data	2023	Change
Price	$0.6529	N/A
Market Cap	$5.33M	N/A
Shares Outstanding	8.16M	-29.05%
Employees	0	N/A
Shareholder Equity	33.15M	-61.06%

Valuation	2023	Change
P/E Ratio	-0.18	N/A
P/S Ratio	357.17	N/A
P/B Ratio	0.16	N/A

Growth	2023	Change
Return on Equity	-0.6500	N/A

Earnings	2023	Change
Revenue	$14.92K	N/A
Earnings	-$21.55M	N/A
EPS	-3.60	N/A
Earnings Yield	-5.51	N/A
Operating Margin	-1.45K	N/A
Net income margin	-1.44K	N/A

Financial Strength	2023	Change
Total Assets	$43.00M	N/A
Total Debt	$533.58K	N/A
Cash on Hand	$18.25M	N/A
Debt to Equity	0.2973	101.52%
Cash to Debt	$34.20	-29.32%
Current Ratio	$4.87	-60.94%